Allergic Rhinitis Due to House Dust Mite Clinical Trial
Official title:
Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12 months.
Condition: - persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication - HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04145219 -
House Dust Mite Allergy Trial In Children
|
Phase 3 | |
| Not yet recruiting |
NCT05510024 -
Radiofrequency Ablation of Bilateral Inferior Turbinate Followed by Subcutaneous Immunotherapy Trial
|
N/A | |
| Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|
||
| Enrolling by invitation |
NCT05960526 -
Nasal Irrigation With Combination of 0.9% NaCl and Binahong Extract (Anredera Cordifolia) 2,5% In Allergic Rhinitis
|
Phase 1 | |
| Active, not recruiting |
NCT04286542 -
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis
|
N/A | |
| Completed |
NCT03654976 -
Mite Asthma Pediatric Immunotherapy Trial
|
Phase 3 |